Updating on the pathogenesis of systemic lupus erythematosus.

Systemic lupus erythematosus (SLE) is a multi-organ autoimmune disease whose pathogenesis is multifactorial lying on genetic, environmental factors and on abnormalities of both the innate and the adaptive immune system. The induction, maintenance and progression of the disease are a multi-step process that may take long time eventually leading to tissue injury. Several genes have been associated to SLE susceptibility; each of them displaying a small effect suggesting the need of an association. However, the gene-gene and gene-environment interactions are still matter of research. Environmental factors, both external such as physical and infectious agents and internal such as gender and hormonal profile, may influence the disease manifestation. SLE is characterized by a complex array of immune abnormalities affecting both the innate and the adaptive immunity. All these processes play a role in the defective clearance of chromatin material that is overexposed to the afferent limb of the immune system leading to an autoimmune response facilitated by defective regulatory mechanisms. The production of a wide panel of autoantibodies represents the ultimate events responsible for tissue aggression. Finally, tissue damage is influenced by the presence of local factors responsible for the final aggressivity of the lesions and of the clinical manifestations.

[1]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[2]  G. Tsokos,et al.  How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. , 2008, Trends in immunology.

[3]  Yuanjia Tang,et al.  MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus. , 2010, Arthritis and rheumatism.

[4]  G. Tsokos,et al.  PP2A Dephosphorylates Elf-1 and Determines the Expression of CD3ζ and FcRγ in Human Systemic Lupus Erythematosus T Cells1 , 2008, The Journal of Immunology.

[5]  Andreas Radbruch,et al.  HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus , 2009, Annals of the rheumatic diseases.

[6]  S. Ojeda,et al.  Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a 2-year longitudinal study , 2009, Annals of the rheumatic diseases.

[7]  Y. Shoenfeld,et al.  Antiphospholipid syndrome dilemmas still to be solved: 2008 status , 2007, Annals of the rheumatic diseases.

[8]  S. Puttonen,et al.  Increased absence due to sickness among employees with fibromyalgia , 2006, Annals of the rheumatic diseases.

[9]  Alain Saraux,et al.  IL-6 Modulates CD5 Expression in B Cells from Patients with Lupus by Regulating DNA Methylation1 , 2009, The Journal of Immunology.

[10]  T. Niewold,et al.  Genetic regulation of serum cytokines in systemic lupus erythematosus. , 2010, Translational research : the journal of laboratory and clinical medicine.

[11]  J. Anolik B cell biology and dysfunction in SLE. , 2007, Bulletin of the NYU hospital for joint diseases.

[12]  D. D'cruz,et al.  Acute Viral Infections in Patients With Systemic Lupus Erythematosus: Description of 23 Cases and Review of the Literature , 2008, Medicine.

[13]  I. Sanz,et al.  B cells as therapeutic targets in SLE , 2010, Nature Reviews Rheumatology.

[14]  B. Diamond,et al.  Phenotypic Characterization of Autoreactive B Cells—Checkpoints of B Cell Tolerance in Patients with Systemic Lupus Erythematosus , 2009, PloS one.

[15]  S. Muller,et al.  Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. , 2010, Journal of autoimmunity.

[16]  Maria Kavai,et al.  Immune complex clearance by complement receptor type 1 in SLE. , 2008, Autoimmunity reviews.

[17]  G. Tsokos,et al.  Systemic lupus erythematosus: new molecular targets , 2007, Annals of the rheumatic diseases.

[18]  R. Nurieva,et al.  Bcl6 Mediates the Development of T Follicular Helper Cells , 2009, Science.

[19]  K. Shokat,et al.  T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR , 2008, Proceedings of the National Academy of Sciences.

[20]  I. Sanz,et al.  Altered B cell receptor signaling in human systemic lupus erythematosus. , 2009, Autoimmunity reviews.

[21]  G. Schett,et al.  Autoimmunity and chronic inflammation - two clearance-related steps in the etiopathogenesis of SLE. , 2010, Autoimmunity reviews.

[22]  A. Puisieux,et al.  Interleukin 17 acts in synergy with B cell–activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus , 2009, Nature Immunology.

[23]  S. Aslanidis,et al.  Parvovirus B19 infection and systemic lupus erythematosus: Activation of an aberrant pathway? , 2008, European journal of internal medicine.

[24]  J. Roudier,et al.  Epstein-Barr virus in autoimmune diseases. , 2008, Best practice & research. Clinical rheumatology.

[25]  L. Truedsson,et al.  Analysis of HLA DR, HLA DQ, C4A, FcγRIIa, FcγRIIIa, MBL, and IL-1Ra allelic variants in Caucasian systemic lupus erythematosus patients suggests an effect of the combined FcγRIIa R/R and IL-1Ra 2/2 genotypes on disease susceptibility , 2004, Arthritis research & therapy.

[26]  Kristin G Ardlie,et al.  Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. , 2004, American journal of human genetics.

[27]  A. Syvänen,et al.  A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5 , 2008, Human molecular genetics.

[28]  Min Chen,et al.  The complement system in systemic autoimmune disease. , 2010, Journal of autoimmunity.

[29]  J. Ioannidis,et al.  The role of FcgammaRIIA and IIIA polymorphisms in autoimmune diseases. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[30]  G. Tsokos,et al.  PP2A dephosphorylates Elf-1 and determines the expression of CD3zeta and FcRgamma in human systemic lupus erythematosus T cells. , 2008, Journal of immunology.

[31]  L. Rönnblom,et al.  Cytokines as therapeutic targets in SLE , 2010, Nature Reviews Rheumatology.

[32]  Kaleb M. Pauley,et al.  Contrast in aberrant microRNA expression in systemic lupus erythematosus and rheumatoid arthritis: is microRNA-146 all we need? , 2009, Arthritis and rheumatism.

[33]  A. Puisieux,et al.  Retraction Note: Interleukin 17 acts in synergy with B cell–activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus , 2014, Nature Immunology.

[34]  P. Lipsky,et al.  Identification and Characterization of a Human CD5+ Pre-Naive B Cell Population1 , 2009, The Journal of Immunology.

[35]  R. Jonsson,et al.  A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans , 2002, Nature Genetics.

[36]  J. Harley,et al.  Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. , 2008, Arthritis and rheumatism.

[37]  J. Erikson,et al.  ICOS expression by effector T cells influences the ability of regulatory T cells to inhibit anti-chromatin B cell responses in recipient mice. , 2010, Journal of autoimmunity.

[38]  M. Oukka,et al.  Expanded Double Negative T Cells in Patients with Systemic Lupus Erythematosus Produce IL-17 and Infiltrate the Kidneys1 , 2008, The Journal of Immunology.

[39]  L. Pasquier,et al.  Orphanet Journal of Rare Diseases , 2006 .

[40]  Y. Shoenfeld,et al.  The geoepidemiology of systemic lupus erythematosus. , 2010, Autoimmunity reviews.

[41]  B. Richardson,et al.  The genetics and epigenetics of autoimmune diseases. , 2009, Journal of autoimmunity.

[42]  J. Alcocer-Varela,et al.  Interleukin 2 and systemic lupus erythematosus: beyond the transcriptional regulatory net abnormalities. , 2009, Autoimmunity reviews.

[43]  L. Truedsson,et al.  Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. , 2010, Blood.

[44]  P. von Landenberg,et al.  Toll-like receptors and autoimmunity. , 2008, Autoimmunity reviews.

[45]  D. Isenberg,et al.  CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. , 2010, Immunity.

[46]  Geoffrey Hom,et al.  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. , 2008, The New England journal of medicine.

[47]  H. Wardemann,et al.  Autoreactive B cell receptors mimic autonomous pre-B cell receptor signaling and induce proliferation of early B cells. , 2008, Immunity.

[48]  L. Peltonen,et al.  AIRE regulates T-cell-independent B-cell responses through BAFF , 2008, Proceedings of the National Academy of Sciences.

[49]  O. Rekvig,et al.  Nuclease deficiencies promote end‐stage lupus nephritis but not nephritogenic autoimmunity in (NZB × NZW) F1 mice , 2011, Immunology and cell biology.

[50]  F. Middleton,et al.  Activation of Mammalian Target of Rapamycin Controls the Loss of TCRζ in Lupus T Cells through HRES-1/Rab4-Regulated Lysosomal Degradation1 , 2009, The Journal of Immunology.

[51]  Igor M. Dozmorov,et al.  Identification of Unique MicroRNA Signature Associated with Lupus Nephritis , 2010, PloS one.

[52]  C. Grimaldi,et al.  Hormonal regulation of B-cell function and systemic lupus erythematosus , 2008, Lupus.

[53]  J. Ioannidis,et al.  The role of FcγRIIA and IIIA polymorphisms in autoimmune diseases , 2004 .

[54]  M. Nambiar,et al.  Differential Expression and Molecular Associations of Syk in Systemic Lupus Erythematosus T Cells1 , 2008, The Journal of Immunology.